.png){kind=icon}
.png){kind=icon}
Return
Pre-shock in acute myocardial infarction: insights from the IABP-SHOCK II and CULPRIT-SHOCK trials
.png){kind=icon}
PRE
AI
H
U
J
A
S
S
S
T
S
H
H
DOI：10.1093/ejhf/xuag231.png)
.png){kind=icon}
Original request for help.png){kind=icon}
Share.png){kind=icon}
Save
Abstract
En 中文
Despite advances in diagnosis and treatment, cardiogenic shock (CS) following acute myocardial infarction (AMI) remains associated with substantial mortality. Within the continuum of CS, the early phases of shock development may represent an important therapeutic window before circulatory failure and irreversible organ injury.1,2 While overt CS has traditionally been defined by the combination of hypotension and hypoperfusion, definitions of earlier shock states vary substantially across studies.3 The subsequently introduced Society for Cardiovascular Angiography and Interventions (SCAI) classification formalized SCAI B as an early stage within the shock trajectory, either determined by isolated hypotension without systemic hypoperfusion or early hypoperfusion despite preserved blood pressure.4 However, data on the clinical characteristics and prognosis of patients with pre-shock remain limited, as they are frequently excluded from randomized trial populations or incorporated into broader shock cohorts.
Journal
IF:
10.8
Papers:
6.6K
Citations:
2.1W
Organization
Cited Papers